Exclusive synthetic biology investor centered on companies replacing industrial inputs with biology-based alternatives, led by a UCSF-trained PhD cell biologist providing deep research expertise and global Latin America–Europe reach. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Ranked by shared stages, industries, geography, cheque size and investor type. 400 related investors in the directory.
Physician-led, immigrant-founded VC built by third-culture founders using cross-cultural insight to back healthcare founders with lived experience and target structural health inequities over generic digital tools. With a disciplined investment approach, the team drives value for both founders and investors.
Thesis-driven TechBio fund oriented toward engineering, computation, and biology, operating a BIOS community platform with podcasts, events, content, and a year-long Venture Residency training future TechBio VCs. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Pre-seed specialist investing at the team and a dream stage in deep-tech applied AI and machine-centric businesses, using a proactive Frontier Curve framework organized around three vectors. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Full-stack creative agency acting as lead creative partner targeting U.S. consumer brands, extending naming, packaging. Standing apart by advertising and go-to-space systems driven by a proprietary cultural-insights engine and offering-culture fit frameworks.
Formative-stage investor allocating around 80% to breakthrough climate technologies (carbon-negative concrete, atmospheric carbon removal), acting as a first believer through a venture-and-philanthropy platform backed by the Fukutake family. The firm continues to build its presence across the venture capital landscape.
Global alternative-protein accelerator with a five-month program (New York, Singapore, Paris), backing consumer and enabling-technology-driven emerging ventures and extending direct access to incumbents like AAK, Bel, Bühler, Givaudan, Tyson Ventures. With a disciplined investment approach, the team drives value for both founders and investors.
